REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > > At Least Three Rings In The Polycyclo Ring System At Least Three Rings In The Polycyclo Ring SystemAt Least Three Rings In The Polycyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/18/07 - 20070015763 - Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist This invention relates to combinations of an atypical antipsychotic, for example ziprasidone, and a dopamine agonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from psychosis and movement disorders associated with Parkinson's disease and subcortical dementias. ... 01/11/07 - 20070010521 - Condensed polycyclic compounds or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same. ... 01/04/07 - 20070004740 - Condensed polycyclic compounds or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same. ... 01/04/07 - 20070004739 - Condensed polycyclic compounds or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same. ... 12/28/06 - 20060293335 - Riboflavin derivative and its manufacture and uses The invention discloses riboflavin derivatives, and a process of preparing the same, and their applications. The w/o suspending preparation of the riboflavin derivatives has high stability, and the effects could last for 3 months after intramuscular injection at dose of 150 mg. This invention increases significantly the bioavailability of riboflavin ... 12/14/06 - 20060281752 - Method for the normalization of sexual response and amelioration of long term genital tissue degradation The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective ... 11/16/06 - 20060258665 - Bridged ring nk1 antagonists or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough. ... 11/16/06 - 20060258664 - Method for the production of riboflavin of modification b/c in granular form The present invention relates to an improved process for preparing pure riboflavin (vitamin B2) of the B/C modification in granule form. Furthermore, the invention relates to pure riboflavin in granule form which has a bulk density to be determined in accordance with DIN 53468 of from 0.45 to 0.7 g/ml ... 11/09/06 - 20060252761 - Augmentation of extinction via administration of sub-antimicrobial doses of d-cycloserine Methods are provided for facilitating psychological extinction of a deleterious, high-anxiety response that is disproportionate to the threat offered by a given stimulus. An afflicted subject is treated with a sub-antimicrobial dose of D-cycloserine in conjunction with extinction training. The methods are relevant for treatment of anxiety disorders, including phobic ... 09/21/06 - 20060211700 - (r)-8,9-dichloro-2,3,4,4a-tetrahydro-1h,6h-pyrazino[1,2-a]quinoxalin-5-one for controlling iop and treating glaucoma Compositions and methods for controlling intraocular pressure and treating glaucoma using (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one are disclosed. ... 08/31/06 - 20060194808 - Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). ... 08/31/06 - 20060194807 - Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 Novel pyrazole compounds such as compounds of the formula (I): (where A, A1, A2, B, R11, W, X, Y and Z are as defined herein) in which the pyrazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of ... 08/10/06 - 20060178368 - Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation Use of a combination of two vitamin compounds, i.e. riboflavin (also known as vitamin B2) and nicotinic acid (also referred to as niacin) or, as an alternative thereto, the corresponding amide, i.e. nicotinamide or niacinamide (also known as vitamin PP) for the systemic treatment of various forms of itching, such ... 08/03/06 - 20060173011 - Treatment of inflammatory disorders with praziquantel Methods of treating and/or preventing disorders mediated by one or more of TNF-α, NF-κB, IKK-α, IKK-β, ATF-2 and p38 kinase by administration of praziquantel, or a pharmaceutically acceptable salt, prodrug, ester or amide thereof. These disorders include inflammatory disorders such as autoimmune diseases. ... 07/20/06 - 20060160816 - Pirazino(aza) indole derivatives and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea. ... 07/20/06 - 20060160815 - Pyrrolo[1,2-a]quinoxalin-5-(4h)-yl)sulfonyls and carbonyls and their use as estrogenic agents wherein R1 to R7, R9 and R10 X, Y, and Z are as defined in the specification; or a pharmaceutically acceptable salt thereof. ... 07/13/06 - 20060154932 - Pharmaceutical compositions and method of treating parkinson's disease This invention is directed to the use of certain pharmaceutical compositions for treating and methods of treating Parkinson s disease. In particular, this invention is directed to pharmaceutical compositions for treating and methods of treating Parkinson s disease comprising the use of selective cyclooxygenase-2 inhibitors, such as rofecoxib, etoricoxib, celecoxib ... 06/15/06 - 20060128713 - Bi- and tricyclic substituted phenyl methanones R7, m and n are as defined in the specification, and to pharmaceutically active acid addition salts thereof. The compounds of the invention are useful in the treatment of neurological and neuropsychiatric disorders. ... 05/18/06 - 20060106024 - Microbicidal composition A microbicidal composition containing: (a) 1,2-benzisothiazolin-3-one; and (b) at least one microbicide selected from among benzalkonium chloride, benzethonium chloride, benzyl alcohol, caprylyl glycol, chlorphenesin, 2,2′-dithiobis(N-methylbenzamide), diazolidinyl urea, ethylenediamine tetraacetic acid, ethylparaben, imidazolidinyl urea, methylparaben, phenoxyethanol, linoleamidopropyl PG-dimonium chloride phosphate, cocamidopropyl PG-dimonium chloride phosphate, propylparaben, cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride, dehydroacetic acid or its ... 03/16/06 - 20060058310 - Remedies for vertebral canal stenosis wherein all the symbols represent the same meaning as described in the specification; a salt of its acid when R3a represents hydrogen, or solvate thereof The therapeutic agent of the present invention is effective for prevention and/or therapy for spinal canal stenosis and the like, such as lumbar spinal canal ... 02/16/06 - 20060035900 - Crystalline forms of ( 6r)-l-erythro-tetrahydrobiopterin dihydrochloride Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations. ... 02/02/06 - 20060025419 - Imidazoquinoxaline compound for the treatment of melanoma The present invention concerns a (4(2′-aminoethyl)amino-1,8-dimethylimididazo(1,2-a)quinoxaline)-4,5-dihydro-1,8-dimethylimidazo(1,2-a)quinoxalin-4-one-2-carboxylic acid (BMS-345541) or an analog thereof for the treatment of melanoma cancer. This compound inhibits NFκB activity and expression, and induces apoptosis in melanoma cancer cells. The present invention also provides a method for assaying for the inhibition of melanoma cancer cell growth. ... 12/22/05 - 20050282813 - Fused cyclic modulators of nuclear hormone receptor function wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7′ or NR10, and M′ is a bond or NR10, with the proviso that at least one of M or M′ must be a bond; E is C=Z2, CR7CR7′, SO2, P═OR2, ... 10/27/05 - 20050239789 - Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage ... 10/13/05 - 20050227988 - Tyrosine kinase inhibitors The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, ... 10/06/05 - 20050222158 - Method of treating migraine headaches using calcitonin gene related peptide mimetics Methods of treating migraine comprising conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides are disclosed. The compounds of the present invention of Formula I have valuable pharmacological properties based on their ability to selectively antagonize calcitonin gene-related peptide (CGRP) receptor for acute and ... 09/29/05 - 20050215558 - Methods of identifying responders to dopamine agonist therapy The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein ... 08/18/05 - 20050182063 - Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands Disclosed herein are compounds that bind to a neuronal nicotinic acetylcholine receptor. These compounds posses broad therapeutic use including the treatment of senile dementia, Alzheimer's disease, Parkinson's disease, attention deficit disorder, and the treatment of addictive disorders such as the use of tobacco in smoking or the use of other ... 07/21/05 - 20050159422 - Inhibitors of akt activity The present invention is directed to compounds comprising a ring-fused quinoxalinyl moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. ... 07/07/05 - 20050148592 - Use of riboflavin and flavin derivatives as chitinase inhibitors The invention relates to the use of riboflavin and of flavin derivatives with chitinase-inhibitory action for controlling arthropods, nematodes and chitin-containing fungi. ... ### FreshPatents.com Support |